Market research
YMAB Y mAbs Therapeutics
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 391M
- P/E ratio
- Not available
- Analyst target
- 8.6
- Dividend yield
- Not available
- Beta
- 0.53
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US9842411095
- Market cap
- 391M
- P/E ratio
- Not available
- Analyst target
- 8.6
- Dividend yield
- Not available
- Beta
- 0.53
About
About Y mAbs Therapeutics
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of radioimmunotherapy and antibody based therapeutic products for the treatment of cancer. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company also develops DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumors; and Omburtamab, an antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma. In addition, it engages in the development of CD38-SADA and GD2-GD3 Vaccine; and offers self-assembly disassembly pretargeted radioimmuno therapy (SADA PRIT) technology platform to deliver the radioactive payload to the tumor. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. It operates in the United States, Western Europe, Eastern Asia, Latin America, Western Asia, and internationally. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in Princeton, New Jersey. As of September 15, 2025, Y-mAbs Therapeutics, Inc. operates as a subsidiary of SERB S.A.S.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the YMAB discussion.
5 years, 4 months ago
Y-mAbs Therapeutics, Inc is currently in a long term downtrend where the price is trading 20.5% below its 200 day moving average.
From a valuation standpoint, the stock is 95.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 59.2.
Y-mAbs Therapeutics, Inc's total revenue rose by inf% to $21M since the same quarter in the previous year.
Its net income has increased by 13.8% to $-20M since the same quarter in the previous year.
Finally, its free cash flow grew by 31.0% to $-18M since the same quarter in the previous year.
Based on the above factors, Y-mAbs Therapeutics, Inc gets an overall score of 4/5.